You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 203093


✉ Email this page to a colleague

« Back to Dashboard


NDA 203093 describes VITEKTA, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are three patents protecting this drug. Additional details are available on the VITEKTA profile page.

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this compound. Additional details are available on the elvitegravir profile page.
Summary for 203093
Tradename:VITEKTA
Applicant:Gilead Sciences Inc
Ingredient:elvitegravir
Patents:3
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 203093
Generic Entry Date for 203093*:
⤷  Get Started Free
Constraining patent/regulatory exclusivity:
7,635,704*PED
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength85MG
Approval Date:Sep 24, 2014TE:RLD:Yes
Patent:7,176,220*PEDPatent Expiration:Feb 27, 2027Product Flag?Substance Flag?Delist Request?Y
Patent:7,635,704*PEDPatent Expiration:Apr 26, 2027Product Flag?Substance Flag?Delist Request?Y
Patent:8,981,103*PEDPatent Expiration:Apr 26, 2027Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links